THORLNC and posterior cortical atrophy: Indeed, for this combined group, THOR showed to be able to stratify patients into particularly low risk of recurrence (only 5% of patients with THOR non-hypermethylated PCa experienced biochemical recurrence within the first 5 years (Figure 2C)) while THOR hypermethylation increased the risk of recurrence by more than 6 fold (Table 1).